Cardiff Oncology shareholders will vote on October 22, 2026, on increasing authorized Capital Stock from 170,000,000 to 320,000,000 shares and authorized common stock from 150,000,000 to 300,000,000 shares. Approval would give the company flexibility to issue authorized shares for Business purposes without another stockholder vote, while adjournment could allow further proxy solicitation.

Key Highlights

  • Cardiff Oncology’s authorized common stock would rise from 150,000,000 to 300,000,000 shares under Proposal 1.
  • Stockholders of record as of August 26, 2026, are entitled to vote at the special meeting.
  • Proposal 2 would permit an adjournment if additional proxies are needed to secure approval of Proposal 1.

Cardiff Oncology, Inc. (NASDAQ: CRDF) will ask shareholders on October 22, 2026, to approve an amendment increasing authorized capital stock from 170,000,000 to 320,000,000 shares. The same measure would increase authorized common stock from 150,000,000 to 300,000,000 shares. A second proposal would allow the special meeting to be adjourned if additional proxy votes are needed for the share authorization amendment.

Share Authorization Goes to Vote

Proposal 1 covers changes to the company’s Amended and Restated Certificate of Incorporation. The current authorization consists of 150,000,000 common shares and 20,000,000 preferred shares.

The proposed amendment would affect the authorized capital stock and common stock totals, while leaving the authorized preferred stock unchanged. The common stock has a Par Value of $0.0001 per share, and the preferred stock has a par value of $0.001 per share.

Cardiff Oncology said the additional authorized but unissued common shares would provide greater flexibility for potential business needs. The company could issue shares from time to time for proper business purposes without the expense and delay of seeking another stockholder approval.

The board approved and declared advisable the certificate amendment on August 12, 2026.

Common Stock Rights Stay Aligned

The proposed additional common shares would carry rights identical to those of the currently outstanding common stock. If the amendment is adopted and approved, Cardiff Oncology intends to file it with the Secretary of State of Delaware as soon as practicable, subject to the board’s discretion.

Adjournment Could Extend Proxy Solicitation

The authority would apply if the meeting does not have enough votes to adopt and approve Proposal 1. Stockholders may vote by internet, mail or in person at the special meeting.

Peers Moving on This News

Source(s)

  • https://www.sec.gov/Archives/edgar/data/1213037/000119312526368249/crdf_def_14a_special_pro.htm